Qiagen (NYSE:QGEN - Free Report) - Equities researchers at Zacks Research decreased their Q3 2025 earnings per share (EPS) estimates for Qiagen in a research note issued to investors on Monday, April 29th. Zacks Research analyst M. Mondal now anticipates that the company will post earnings of $0.55 per share for the quarter, down from their previous forecast of $0.57. The consensus estimate for Qiagen's current full-year earnings is $2.09 per share. Zacks Research also issued estimates for Qiagen's Q4 2025 earnings at $0.61 EPS.
Qiagen (NYSE:QGEN - Get Free Report) last issued its quarterly earnings results on Monday, April 29th. The company reported $0.46 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.44 by $0.02. Qiagen had a return on equity of 12.50% and a net margin of 17.38%. The firm had revenue of $459.00 million during the quarter, compared to analyst estimates of $453.91 million. During the same period last year, the company earned $0.53 EPS. Qiagen's quarterly revenue was down 5.4% compared to the same quarter last year.
Other analysts have also issued reports about the stock. Stifel Nicolaus lowered their price objective on shares of Qiagen from $55.00 to $45.00 and set a "hold" rating for the company in a research note on Wednesday. Morgan Stanley raised Qiagen from an "equal weight" rating to an "overweight" rating and increased their target price for the company from $49.48 to $51.00 in a research report on Friday, February 16th. JPMorgan Chase & Co. upped their price objective on Qiagen from $50.00 to $52.00 and gave the stock an "overweight" rating in a research note on Thursday, February 8th. Finally, Citigroup reduced their target price on shares of Qiagen from $61.86 to $60.00 and set a "buy" rating for the company in a report on Thursday, February 8th. Four investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat, Qiagen has an average rating of "Moderate Buy" and an average price target of $50.95.
Check Out Our Latest Report on QGEN
Qiagen Trading Up 1.1 %
Shares of Qiagen stock traded up $0.48 on Wednesday, hitting $42.81. 1,467,683 shares of the company traded hands, compared to its average volume of 1,228,328. The company has a current ratio of 1.99, a quick ratio of 1.62 and a debt-to-equity ratio of 0.24. The company has a market cap of $9.77 billion, a PE ratio of 28.38, a PEG ratio of 3.58 and a beta of 0.41. The stock's 50 day moving average price is $42.56 and its 200-day moving average price is $42.71. Qiagen has a 52 week low of $34.74 and a 52 week high of $47.70.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently made changes to their positions in the business. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Qiagen by 97.7% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 263,016 shares of the company's stock worth $11,900,000 after buying an additional 130,006 shares in the last quarter. Van ECK Associates Corp increased its holdings in shares of Qiagen by 3.1% in the first quarter. Van ECK Associates Corp now owns 208,587 shares of the company's stock valued at $8,967,000 after purchasing an additional 6,361 shares during the last quarter. Allspring Global Investments Holdings LLC boosted its stake in Qiagen by 25.6% during the first quarter. Allspring Global Investments Holdings LLC now owns 1,689,763 shares of the company's stock worth $72,643,000 after buying an additional 344,275 shares during the last quarter. Commonwealth Equity Services LLC purchased a new stake in Qiagen in the 1st quarter valued at $596,000. Finally, Principal Financial Group Inc. increased its stake in shares of Qiagen by 28.6% in the 1st quarter. Principal Financial Group Inc. now owns 18,693 shares of the company's stock worth $804,000 after acquiring an additional 4,158 shares during the last quarter. Hedge funds and other institutional investors own 70.00% of the company's stock.
About Qiagen
(
Get Free Report)
QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.
Featured Articles
Before you consider Qiagen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Qiagen wasn't on the list.
While Qiagen currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
